ArticleJournal of health monitoring2025
Waterpipe use in Germany (2018 - 2024): Prevalence and sociodemographic differences in age of initiation.
Article in Journal of health monitoring, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Waterpipe (WP) use poses not only a risk of nicotine dependence but also additional health hazards. This study examined trends in WP use in Germany, focusing on prevalence by age group and differences in initiation age. Methods: We analysed data from 76,239 respondents (≥ 14 years) from the German Study on Tobacco Use (DEBRA); a series of bi-monthly national surveys using face-to-face interviews at home (2018 - 2024). Prevalence trends were modelled using binomial logistic regression models with restricted cubic splines. Results: The prevalence of WP use decreased over time, to an estimated 0.9 % (95 % CI = 0.6 - 1.2) by mid-2024. This prevalence is made up of 0.1 % (95 % CI = 0.0 - 0.2) 14- to 17-year-olds, 0.3 % (95 % CI = 0.2 - 0.6) 18- to 24-year-olds, 0.3 % (95 % CI = 0.2. - 0.4) 25- to 39-year-olds, and 0.2 % (95 % CI = 0.1 - 0.3) people aged 40 years and older. WP use increased until 2020 up to 2.8 % (95 % CI = 2.3 - 3.4), remained stable for two years and then decreased, especially among people between 25 and 39 years of age. The proportion of 14- to 17-year-old users and users aged at least 40 years remained stable over the years at a low level. Median initiation age was 18 years (25th percentile: 16 years; 75th percentile: 22 years). A lower initiation age was associated with male gender and lower income. Conclusions: WP use increased from 2018 - 2020, stabilised from 2020 - 2022, and then decreased until 2024. Median initiation age was 18, with males and people with lower income starting at a younger age. Targeted public health interventions, focusing on younger males and those with lower socioeconomic status, are needed to prevent early use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.